Clinical Trials Logo

Early-Stage Breast Carcinoma clinical trials

View clinical trials related to Early-Stage Breast Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06387173 Recruiting - Clinical trials for Early Stage Breast Carcinoma

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer

Start date: January 4, 2024
Phase:
Study type: Observational

This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.

NCT ID: NCT06113016 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors

PROFFi
Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.

NCT ID: NCT05945290 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

Start date: July 7, 2022
Phase:
Study type: Observational

This study evaluates pre-analytical factors affecting circulating tumor deoxyribonucleic acid (ctDNA) analysis in breast cancer that not spread beyond the breast and or lymph nodes (early and locally advanced). ctDNA refers to freely circulating tumor DNA fragments found in the blood plasma. Pre-analytical factors such as blood collection tubes, delays in separation of plasma, centrifugation speeds, storage conditions, shipping and DNA extraction methods can all affect ctDNA measurements. Inappropriate processing can cause breaking down of the membrane (lysis) of peripheral blood cells that release background wild-type DNA and may also cause degradation of circulating tumor-specific DNA fragments. Both mechanisms will dilute levels of ctDNA in plasma and make it more difficult to detect. Evaluating the pre-analytical factors of the collection of blood and left over tissue samples for the research of cancer may help researchers to evaluate the impact of the blood collection/processing and long-term storage from patients with locally advanced breast cancer.

NCT ID: NCT05417867 Recruiting - Clinical trials for Early Stage Breast Carcinoma

Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Stage I-III Breast Cancer

Start date: April 14, 2021
Phase:
Study type: Observational

This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for stage I-III breast cancer. Patients undergoing chemotherapy may experience nausea as a result of their treatment. Known risk factors for CIN do not explain the differences in CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with CIN.

NCT ID: NCT05368428 Recruiting - Clinical trials for Chemotherapy-Induced Peripheral Neuropathy

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Start date: October 19, 2022
Phase: N/A
Study type: Interventional

This phase II trial examines transcutaneous electrical nerve stimulation (TENS) in patients with stage I-III breast cancer with chemotherapy induced peripheral neuropathy. TENS is a procedure in which mild electric currents are applied to some areas of the skin to potentially improve neuropathy. This trial may help determine if TENS is feasible and effective for the treatment of peripheral neuropathy symptoms while on chemotherapy.

NCT ID: NCT04290897 Recruiting - Clinical trials for Anatomic Stage II Breast Cancer AJCC v8

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Start date: September 29, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in the brain that could be contributing to cognitive complaints seen after cancer treatments.

NCT ID: NCT02947425 Recruiting - Clinical trials for Early-Stage Breast Carcinoma

TARGeted Intraoperative radioTherapy (TARGIT) Registry Database

TARGIT R
Start date: July 2013
Phase:
Study type: Observational [Patient Registry]

This is a prospectively registered database of patients with early breast cancer who will be treated with radiotherapy during surgery. More than 2000 women have already received this treatment in clinical trials. This study will monitor the health status of women who receive this treatment outside of a clinical trial, especially those who might not have been eligible for the original clinical trials. The aim is to confirm the long-term effectiveness and safety of the technique.

NCT ID: NCT02889874 Recruiting - Clinical trials for Early Stage Breast Carcinoma

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

EXPERT
Start date: August 21, 2017
Phase: N/A
Study type: Interventional

This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.

NCT ID: NCT02511301 Recruiting - Clinical trials for Early-Stage Breast Carcinoma

Circadian Thermal Sensing to Detect Breast Disease

Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if Cyrcadia's Circadian Biometric Recorder (CBR™), which is attached to soft biometric patches worn on the body, can improve early breast cancer detection along with mammography or as a stand alone device.